In Brief: Pruritus Following Antihistamine Discontinuation

The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H1-antihistamines cetirizine (Zyrtec, and others) and levocetirizine (Xyzal, and others) about the risk of severe pruritus following discontinuation of treatment.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-08-18
DOI
https://doi.org/10.58347/tml.2025.1735e
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Brief: Pruritus Following Antihistamine Discontinuation

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Dermatology and Skin Diseases
article

In Brief: Pruritus Following Antihistamine Discontinuation

article en

Abstract

The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H1-antihistamines cetirizine (Zyrtec, and others) and levocetirizine (Xyzal, and others) about the risk of severe pruritus following discontinuation of treatment.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1735)
Openalex Percentile: Top 64%
Dermatology and Skin Diseases
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

In Brief: Pruritus Following Antihistamine Discontinuation · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS